Nuvation Bio (NUVB) Stock Price

Nuvation Bio Price

NYSE·CLOSED
4.94
​
Market closed

Nuvation Bio's net margin stands at -325.3%, up from -7,213.8% several years earlier. Analysts set a median price target of 11.22 USD, implying 127.1% above the current price. Of 17 analysts, 15 rate the stock a buy — an overall Buy consensus.

Nuvation Bio stock price

Access this data via the Eulerpool API

Nuvation Bio business model & stock analysis

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2020-07-01. The firm is focused on developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company’s clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. The company has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its drug-drug conjugate (DDC) platform is a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Frequently asked questions about Nuvation Bio

Analysts currently set an average price target of 11.63 USD for the Nuvation Bio stock (median: 11.22 USD), implying +135.4 % versus the latest price. The consensus is based on 17 analyst ratings.

18 analysts currently rate the Nuvation Bio stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Nuvation Bio to generate revenue of 196.02 M USD and earnings per share of -0.40 USD.

Converted at the current exchange rate, the Nuvation Bio share trades at 4.41 EUR (4.94 USD).

The Nuvation Bio share (NUVB) is listed on 1 stock exchanges, including: NYSE (NUVB).

The expected revenue of Nuvation Bio is 196.02 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Nuvation Bio is -136.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Nuvation Bio is currently -12.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nuvation Bio stock.

The price-to-sales ratio (P/S) of Nuvation Bio is currently 8.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nuvation Bio stock.

The Eulerpool Quality Score for Nuvation Bio is 3/10.

The ISIN of Nuvation Bio is US67080N1019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Nuvation Bio is NUVB. The ticker symbol is used to trade Nuvation Bio shares on the stock exchange.

Fair ValueTerminal
4.94 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
211,080.54 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jul 1, 2020
ISIN
US67080N1019
Cusip
67080N101
Market capitalization
1.69 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-12.44
P/Ee 2027
-26.91
P/Ee 2028
207.46
P/Ee 2029
105.86
P/Ee 2030
8.90
P/Se
8.68
EV/EBIT
—
P/B Ratio
5.54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.76 %
Last updated Oct 11, 2026, 4:43 PM

Nuvation Bio Peer Group

Nuvation Bio Ticker

NEW YORK · NUVB

Nuvation Bio FIGI

NUVB:US · BBG00VHJ0CC1NUVB:UA · BBG00WRF04H9NUVB:UC · BBG00WRF04J7NUVB:UN · BBG00WRF04L4NUVB:UP · BBG00WRF04M3NUVB:UB · BBG00WRF04P0NUVB:UT · BBG00WRF04Q9NUVB:UM · BBG00WRF04R8NUVB:UX · BBG00WRF04S7NUVB:UD · BBG00WRF04Y0NUVB:UF · BBG00WRF0513NUVB:VY · BBG00WRF0522

All fundamentals and in-depth analysis of Nuvation Bio

Our stock analysis for Nuvation Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuvation Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.